PLoS ONE (Jan 2018)

TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients.

  • Eriza Cristina Hahn,
  • Camila Matzenbacher Bittar,
  • Fernanda Sales Luis Vianna,
  • Cristina Brinckmann Oliveira Netto,
  • Jorge Villanova Biazús,
  • Rodrigo Cericatto,
  • José Antônio Cavalheiro,
  • Márcia Portela de Melo,
  • Carlos Henrique Menke,
  • Eliane Rabin,
  • Sandra Leistner-Segal,
  • Patricia Ashton-Prolla

DOI
https://doi.org/10.1371/journal.pone.0209934
Journal volume & issue
Vol. 13, no. 12
p. e0209934

Abstract

Read online

Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1-1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93-5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios.